|
|
|
Forums33
Topics44,198
Posts519,920
Members14,186
| |
Most Online11,978
Nov 21st, 2025
|
|
Administrator/owner:
John (Dragonslayer)
Administrator:
Melinda (mig)
WebAdmin:
Timo (Timo)
Administrator:
Brad (wolverinefan)
Moderators:
· Tim (Dotyisle)
· Chelsea (Kiwi)
· Megan (Megan)
· Wendy (WendyR)
· John (Cheerful)
· Chris (fyrfytr187)
|
|
If you want to use this QR code (Quick Response code) just save the image and paste it where you want. You can even print it and use it that way. Coffee cups, T-Shirts etc would all be good for the QR code.
|
|
|
|
Joined: Jun 2007
Posts: 531
Veteran_AS_Kicker
|
OP
Veteran_AS_Kicker
Joined: Jun 2007
Posts: 531 |
found some good study data that AS pt.s were doing well on it.
so asked my rheumy and got some samples.
works really well and really fast.
just upsetting my stomach a little, better on empty stomach.
|
|
|
|
|
Joined: Jul 2012
Posts: 87
Apprentice_AS_Kicker
|
|
Apprentice_AS_Kicker
Joined: Jul 2012
Posts: 87 |
hi Finnari
i heard about someone with AS that get very good results with
tofacinitib(Xeljanz).
and just like me inflammatory indicator in his blood was normal
crp and sedim .
and he didn t have much suchess with tnf.
|
|
|
|
|
Joined: Jun 2007
Posts: 531
Veteran_AS_Kicker
|
|
OP
Veteran_AS_Kicker
Joined: Jun 2007
Posts: 531 |
yea jeffo I don't have any blood indicators that are abnormal.
TNF inhibitors used to work real well for me then I got allergic to all of them due to the mouse proteins.
so this is a good alternative.
|
|
|
|
|
Joined: Jul 2012
Posts: 87
Apprentice_AS_Kicker
|
|
Apprentice_AS_Kicker
Joined: Jul 2012
Posts: 87 |
Xeljang put you on remission?
|
|
|
|
|
Joined: Apr 2002
Posts: 3,607
|
|
Joined: Apr 2002
Posts: 3,607 |
That's great news! Just did a search and found its recently been approved in Canada too, but doesn't seem to be covered in my province yet.
Mind if I ask how much an out of pocket prescription costs?
Hope you continue to get good results with it!
|
|
|
|
0 members (),
3,500
guests, and
348
robots. |
|
Key:
Admin,
Global Mod,
Mod
|
|
|
|
|
|
